Full-year 2025 revenue reached $212.7 million, an increase of 2% compared to $209.4 million in 2024. Fourth quarter 2025 revenue was $62.5 million, a decrease of 9% compared to $68.7 million in the fourth quarter of 2024, primarily driven by a shift in product sales toward lower-priced bunion kits. Full-year 2025 net loss was $(59.0) million, compared to a net loss of $(55.7) million in 2024. Fourth quarter 2025 net loss was $(9.4) million, compared to $(0.5) million for the same period in 2024. Full-year 2025 Adjusted EBITDA loss was reduced by 64% to $(3.9) million, compared to $(11.0) million in 2024. Fourth quarter 2025 Adjusted EBITDA was $6.2 million, compared to $11.1 million for the same period in 2024. Cash usage was reduced by 46% to $27.3 million in full-year 2025, compared to $50.5 million in full-year 2024. The company increased net new active surgeons by 202 for full-year 2025, ending the year with 3,337 active surgeons, a 6% increase. The global patent portfolio now totals 135 granted patents in addition to 199 pending patent applications. For full-year 2026, the company is initiating revenue guidance of $200 million to $212 million, representing a decline of 6% to 0% compared to full-year 2025. The company expects an Adjusted EBITDA loss in the range of $4.0 million to $6.0 million for full-year 2026, compared to a loss of $3.9 million in full-year 2025. A reduction in cash usage of approximately 50% is expected for full-year 2026 compared to full-year 2025.